Form 4: Panbela Therapeutics CFO Granted Stock Options

Susan Horvath, CFO of Panbela Therapeutics, received stock options for 25,480 shares on October 1, 2024.

Summary

• Susan Horvath, the V.P. of Finance & CFO of Panbela Therapeutics, Inc. (PBLA), was granted stock options.
• The transaction occurred on October 1, 2024.
• Horvath received options to purchase 25,480 shares of common stock at an exercise price of $0.389 per share.
• The options vest fully on October 1, 2025, contingent upon continuous service with the company.
• The options expire on October 1, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance, but it's not a major event.

Positives

• The granting of stock options to the CFO aligns her interests with those of the shareholders.
• The vesting schedule incentivizes continued service with the company.

Industry Context

Granting stock options to executives is a common practice in the pharmaceutical industry to incentivize performance and align management's interests with those of shareholders. This is a standard compensation practice.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to incentivize their executives.
• The size of the grant is relative to the size of the company and the executive's role; this grant appears consistent with industry norms for a company of Panbela's size.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns management's interests with increasing shareholder value.
• The CFO is incentivized to contribute to the company's success to realize the value of the options.

Key Dates

Keywords

stock options, Panbela Therapeutics, PBLA, CFO, Susan Horvath, Form 4, executive compensation